Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-3795 + cabozantinib
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MK-3795 + cabozantinib is an investigational combination therapy for cancer, specifically studied in advanced clear cell renal cell carcinoma (ccRCC). MK-3795, previously known as PT2385, is a first-generation small molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α), a transcription factor implicated in the pathogenesis of ccRCC due to frequent loss-of-function mutations in the VHL gene. By inhibiting HIF-2α, MK-3795 disrupts expression of genes promoting tumor growth and angiogenesis. Cabozantinib is an approved multikinase inhibitor targeting receptors involved in tumor growth and angiogenesis, including MET, VEGFR, and AXL. The combination seeks to simultaneously target both the hypoxic response and angiogenic signaling in ccRCC to enhance antitumor efficacy.
- Other names
- belzutifan precursor + cabozantinib
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)AXL (AXL receptor tyrosine kinase)NTRK2 (Tropomyosin-related kinase receptor type B)EPAS1 (Hypoxia-inducible factor 2-alpha)ROS1 (Proto-oncogene tyrosine-protein kinase ROS)TEK (Angiopoietin-1 receptor)MET (Mesenchymal-epithelial transition factor receptor)VEGFR2 (Vascular endothelial growth factor receptor 2)RET (Rearranged during transfection receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on MK-3795 + cabozantinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-3795 + cabozantinib.